Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03466229
Other study ID # Androferti
Secondary ID
Status Completed
Phase N/A
First received March 4, 2018
Last updated March 14, 2018
Start date July 1, 2015
Est. completion date December 31, 2016

Study information

Verified date March 2018
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.


Description:

In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.

Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.

Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.

The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.

Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.

The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .

The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date December 31, 2016
Est. primary completion date December 31, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Referred due to infertility

2. Age: 18-50 years,

3. Non-smoking,

4. Sperm DNA Fragmentation Index >25%

Exclusion Criteria:

1. Body mass index (BMI) =30,

2. FSH outside the normal range of 2-8 IU/L,g)

3. LH outside the normal range of 2-10 IU/L,

4. T < 10nmol/L

5. Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,

6. History of anabolic steroids use,

7. Taking antioxidant supplementation the last six months.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Androferti

Placebo


Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Region Skane Octean, Q-Pharma

Outcome

Type Measure Description Time frame Safety issue
Primary DFI_3 3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Change in DNA Fragmentation Index from Baseline to 3 months
Primary DFI_6 6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay Change in DNA Fragmentation Index from Baseline to 6 months
Secondary Concentration_3 Change sperm concentration 3 months Change in sperm concentration from baseline to 3 months in millions/mL
Secondary Concentration_6 Change sperm concentration 6 months Change in sperm concentration from baseline to 6 months in millions/mL
Secondary Motility_3 Change sperm motility 3 months Change in sperm motility from baseline to 3 months in %
Secondary Motility_6 Change sperm motility 6 months Change in sperm motility from baseline to 6 months in %
Secondary Morphology_3 Change sperm morphology 3 months Change in sperm morphology from baseline to 3 months in %
Secondary Morphology_6 Change sperm morphology 6 months Change in sperm morphology from baseline to 6 months in %
See also
  Status Clinical Trial Phase
Recruiting NCT05503862 - Home Semen Testing in Men Beginning Attempts to Conceive N/A
Recruiting NCT03307655 - Relationship Between Nitric Oxide (NO) in Follicular Fluid and Sperm Fertilization Ability N/A
Withdrawn NCT02839447 - A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
Completed NCT00975117 - Spermotrend in the Treatment of Male Infertility Phase 3
Completed NCT00756561 - HOP-2A - Intratesticular Hormone Levels N/A
Recruiting NCT04541459 - Validation of New Devices Against Ambient Electromagnetic Radiation Early Phase 1
Completed NCT02889341 - Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility N/A
Not yet recruiting NCT03167008 - Vitamin D Level vs Semen Parameters
Completed NCT02268123 - Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation
Completed NCT01232465 - Impact of Sperm DNA Integrity on In Vitro Cycles N/A
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Completed NCT03552081 - Tobacco and Sperm Genome: Effects of Smoking Cessation N/A
Recruiting NCT05200663 - Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility Phase 2
Completed NCT02025270 - MSCs For Treatment of Azoospermic Patients Phase 1/Phase 2
Recruiting NCT06147700 - Identifying Molecular Determinants of Infertility in Men (MODIFY)
Recruiting NCT06188936 - Home Semen Analysis Tests as a Screening Tool for Fertility Patients N/A
Recruiting NCT04200118 - Epigenetic and Genetic Effects in Cancer Patients: Analysis Pre and After Treatment
Terminated NCT02605070 - Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia Phase 3
Completed NCT01407432 - Impact of Folates in the Care of the Male Infertility Phase 3
Completed NCT00596739 - A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery N/A